The results revealed a significant effect of the 90-day supplementation with B. breve postbiotic extract on changes in CRP, IL-6 levels... and induced protective changes in inflammatory markers.

Improvements were observed for some blood parameters related to liver functions and inflammation, such as γ-glutamyltranspeptidase and high-sensitivity C-reactive protein.

Then, it can reduce pro-inflammatory cytokines release, adjust immune dysfunction, and inhibit TLR4-MyD88-dependent pathways and downstream inflammatory pathways to alleviate joint inflammation in CIA rats.

The proportion of neonates with detectable B. breve increased significantly post intervention: Placebo: \\[S1:2/66 (3%), S2: 25/66 (38%), p<0.001] Probiotic: \\[S1: 29/74 (40%), S2: 67/74 (91%), p<0.001]. Median S1 B. breve counts in both groups were below detection (<4.7 log cells x g(-1)), increasing significantly in S2 for the probiotic group (log 8.6) while remaining <4.7 log in the control group (p<0.001).

In human feeding experiments, the administered B. breve was recovered at a level of over 10(9) CFU/g faeces, accompanied by an increase in the total number of bifidobacteria.

Adverse events occurred in two extremely premature infants with functional ileus due to starch aggregates as vehicle, and in two surgical neonates with bacteremia caused by B. breve genetically identical to BBG-01, and no serious adverse events with poor outcome were reported.

The number of adverse events was not different between both groups.

Improvements were observed for some blood parameters related to liver functions and inflammation, such as γ-glutamyltranspeptidase and high-sensitivity C-reactive protein.

A significantly lowered fat mass was observed in the B-3 group compared with the placebo group at week 12.

We experienced six cases of B. breve bacteremia and assessed their features retrospectively. The incidence rate of B. breve bacteremia in our hospital was 2% (6/298), higher than reported previously.

death: 8.3% vs. 8.5% [adjusted RR 0.93, 95% CI 0.67 to 1.30]

The Bifidobacterium in fecal samples after initiating BBG-01 in group A were significantly higher in number than that in group B. Enterobacteriaceae were significantly fewer in group A than in group B immediately (7.0 [3.9-7.7] vs. 8.5 [8.0-9.1] log10 cells/g) and 1 week (7.7 [7.0-8.1] vs. 9.3 [8.6-9.5] log10 cells/g) after surgery (p < 0.05 for both comparisons). The number of Pseudomonas after 1 week was significantly lower in group A than in group B (p = 0.04).

Additionally, in the Bb group, infants had better night sleep...

The percentage of reduction in the minutes of crying from baseline in the Bb group was significantly higher than that in the Simethicone group every week of the intervention (-40.3 vs -27.6% at 1-week; -59.2 vs -43.2% at 2-weeks; -64.5 vs -53.5% at 3-week and -68.5 vs -59.5% at 4-weeks, P<0.05).

Biotics Ultra Blend

By Divine Health

Rating: 1 (1 reviews)In Stock

	Amount Per Serving
Prebiotic Blend	200 mg
Fructooligosaccharides (FOS)	-
Glactoogosaccharides (GOS)	-
Probiotic Blend	16 billion CFU
Bacillus coagulans Bacillus coagulans	-
Bacillus subtills Bacillus Subtilis	-
Lactobacillus plantarum N13 Lactobacillus plantarum N13	-
Bifidobacterium breve BBr60 Bifidobacterium breve BBr60	-
Bifidobacterium lactic BLa80 Bifidobacterium lactis BLA80	-

Health Outcomes Supported by Research

Reduced Inflammation Levels2 studies
Altered Gut Microbiota Composition2 studies
Reduced Body Weight2 studies
Increased Fecal Bifidobacteria3 studies
Reduced Colitis Symptoms3 studies

Other ingredients

vegetable capsule (hypromellose)
rice flour

Free of

Pill Type: Capsule

Flavor: -

Serving Size: 1

Servings per Container: 60

UPC: 860010993248

Ask AI a Question Add to List

USD -

USD 43

Bifidobacterium breve BBr60

Biotics Ultra Blend